About
Titles
Hospital Resident
Biography
Martin is an Integrated Interventional Radiology resident at the Yale-New Haven Hospital. He has a particular interest in oncology and global outreach, an interest inspired by the vast opportunities for change in cancer management he identified while growing up in Kenya as well as while conducting cancer research and providing direct/indirect care to patients with cancer at various institutions in the USA. He attended Rice University for college after which he worked as a cancer researcher at the University of Chicago for two years. He received his medical training at Northwestern Feinberg School of Medicine and completed an internship in General Surgery at the Mount Sinai Medical Center in Miami Beach.
Departments & Organizations
- Radiology & Biomedical Imaging
- Radiology Diversity Program
Education & Training
- General Surgery Resident
- Mount Sinai Medical Center (2020)
- MD
- Northwestern Feinberg School of Medicine (2019)
- BS
- Rice University, Biochemistry and Cell Biology (2013)
Research
Research at a Glance
Publications Timeline
A big-picture view of Martin Mutonga's research output by year.
8Publications
Publications
2019
Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Mutonga M, Speedy S, Rademaker A, Liu D, Uthe R, Jain S, Gradishar WJ, Flaum L, Santa-Maria CA. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer. Breast Cancer Res Treat 2019, 176: 95-100. PMID: 30977026, DOI: 10.1007/s10549-018-05088-6.Peer-Reviewed Original Research
2017
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
Santa-Maria CA, Kruse M, Raska P, Weiss M, Swoboda A, Mutonga MB, Abraham J, Jain S, Nanda R, Montero AJ. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers. Breast Cancer Res Treat 2017, 166: 179-184. PMID: 28752189, DOI: 10.1007/s10549-017-4415-1.Peer-Reviewed Original Research
2016
Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection.
Alachkar H, Mutonga M, Kato T, Kalluri S, Kakuta Y, Uemura M, Imamura R, Nonomura N, Vujjini V, Alasfar S, Rabb H, Nakamura Y, Alachkar N. Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection. BMC Nephrol 2016, 17: 181. PMID: 27871261, DOI: 10.1186/s12882-016-0395-3.Peer-Reviewed Original ResearchManagement of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? Oncology (Williston Park) 2016, 30: 148-55. PMID: 26892151.Peer-Reviewed Original Research
2015
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget 2015, 6: 33410-25. PMID: 26450903, DOI: 10.18632/oncotarget.5418.Peer-Reviewed Original ResearchTargeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).
Mutonga M, Tamura K, Malnassy G, Fulton N, de Albuquerque A, Hamamoto R, Stock W, Nakamura Y, Alachkar H. Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Transl Oncol 2015, 8: 368-375. PMID: 26500027, DOI: 10.1016/j.tranon.2015.07.003.Peer-Reviewed Original Research
2014
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
Alachkar H, Mutonga MB, Metzeler KH, Fulton N, Malnassy G, Herold T, Spiekermann K, Bohlander SK, Hiddemann W, Matsuo Y, Stock W, Nakamura Y. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget 2014, 5: 12371-82. PMID: 25365263, DOI: 10.18632/oncotarget.2642.Peer-Reviewed Original Research
2012
Cell-specific multifunctional processing of heterogeneous cell systems in a single laser pulse treatment.
Lukianova-Hleb EY, Mutonga MB, Lapotko DO. Cell-specific multifunctional processing of heterogeneous cell systems in a single laser pulse treatment. ACS Nano 2012, 6: 10973-81. PMID: 23167546, DOI: 10.1021/nn3045243.Peer-Reviewed Original Research
News
News
- August 19, 2020
Welcome New Trainees!